In Vivo Biodistribution of No-Carrier-Added 6-<sup>18</sup>F-Fluoro-3,4-Dihydroxy-l-Phenylalanine (<sup>18</sup>F-DOPA), Produced by a New Nucleophilic Substitution Approach, Compared with Carrier-Added <sup>18</sup>F-DOPA, Prepared by Conventional Electrophilic SubstitutionWillem-Jan Kuik, Philip H. Elsinga, Stephen G. DiMagno et al.|Journal of Nuclear Medicine|2014Cited by 66
Synthesis and Preclinical Evaluation of 2-(2-Furanyl)-7-[2-[4-[4-(2-[<sup>11</sup>C]methoxyethoxy)phenyl]-1-piperazinyl]ethyl]7<i>H</i>-pyrazolo[4,3-<i>e</i>][1,2,4]triazolo[1,5-<i>c</i>]pyrimidine-5-amine ([<sup>11</sup>C]Preladenant) as a PET Tracer for the Imaging of Cerebral Adenosine A<sub>2A</sub> ReceptorsXiaoyun Zhou, Philip H. Elsinga, Shivashankar Khanapur et al.|Journal of Medicinal Chemistry|2014Cited by 34
Development of [<sup>18</sup>F]-Labeled Pyrazolo[4,3-<i>e</i>]-1,2,4- triazolo[1,5-<i>c</i>]pyrimidine (SCH442416) Analogs for the Imaging of Cerebral Adenosine A<sub>2A</sub>Receptors with Positron Emission TomographyShivashankar Khanapur, Philip H. Elsinga, Aren van Waarde et al.|Journal of Medicinal Chemistry|2014Cited by 33